Damora Therapeutics, Inc. (DMRA) stock
DMRANasdaqPharmaceutical PreparationsFiscal year ends December 31
$22.56+0.06 (+0.29%)
Close on Nov 17, 2026Market cap $1.39BP/E 5.7Yield 0.00%
Damora Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Damora Therapeutics's total assets was $532.63M at Sep 30, 2026. For fiscal 2025 it was $260.53M, up 1420.7% from the year before. The highest annual figure on record is $260.53M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $260.53M | +1420.7% |
| FY2024 | Dec 31, 2024 | $17.13M | -55.2% |
| FY2023 | Dec 31, 2023 | $38.23M | -47.8% |
| FY2022 | Dec 31, 2022 | $73.19M | -40.1% |
| FY2021 | Dec 31, 2021 | $122.22M | -28.8% |
| FY2020 | Dec 31, 2020 | $171.60M | +203.1% |
| FY2019 | Dec 31, 2019 | $56.61M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $532.63M | +4861.1% |
| Q2 FY2026 | Jun 30, 2026 | $543.64M | +3870.8% |
| Q1 FY2026 | Mar 31, 2026 | $535.44M | +3384.8% |
| Q4 FY2025 | Dec 31, 2025 | $260.53M | +1420.7% |
| Q3 FY2025 | Sep 30, 2025 | $10.74M | -54.1% |
| Q2 FY2025 | Jun 30, 2025 | $13.69M | -49.8% |
| Q1 FY2025 | Mar 31, 2025 | $15.37M | -52.7% |
| Q4 FY2024 | Dec 31, 2024 | $17.13M | -55.2% |
| Q3 FY2024 | Sep 30, 2024 | $23.38M | -53.3% |
| Q2 FY2024 | Jun 30, 2024 | $27.30M | -53.6% |
| Q1 FY2024 | Mar 31, 2024 | $32.48M | -49.7% |
| Q4 FY2023 | Dec 31, 2023 | $38.23M | -47.8% |
| Q3 FY2023 | Sep 30, 2023 | $50.05M | -39.0% |
| Q2 FY2023 | Jun 30, 2023 | $58.80M | -36.7% |
| Q1 FY2023 | Mar 31, 2023 | $64.63M | -40.7% |
| Q4 FY2022 | Dec 31, 2022 | $73.19M | -40.1% |
| Q3 FY2022 | Sep 30, 2022 | $82.03M | -39.6% |
| Q2 FY2022 | Jun 30, 2022 | $92.86M | -36.8% |
| Q1 FY2022 | Mar 31, 2022 | $108.93M | -31.3% |
| Q4 FY2021 | Dec 31, 2021 | $122.22M | -28.8% |
| Q3 FY2021 | Sep 30, 2021 | $135.87M | +38.4% |
| Q2 FY2021 | Jun 30, 2021 | $146.82M | +159.4% |
| Q1 FY2021 | Mar 31, 2021 | $158.66M | – |
| Q4 FY2020 | Dec 31, 2020 | $171.60M | – |
| Q3 FY2020 | Sep 30, 2020 | $98.15M | – |
| Q4 FY2019 | Dec 31, 2019 | $56.61M | – |
See a number that looks wrong?